BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BC Innovations | Mar 28, 2018
Distillery Techniques


TECHNOLOGY: Gene profiling; SNPs; tissue markers Tumor expression levels of any one of 32 genes could predict survival in estrogen receptor-positive breast cancer. The protocol uses Capture Hi-C -- a method that maps transcriptional start...
BC Innovations | Jun 4, 2015
Distillery Therapeutics

Therapeutics: Cofilin 1 (CFL1); SH3 and multiple ankyrin repeat domains 3 (SHANK3; PROSAP2; SPANK-2)

Neurology INDICATION: Autism Mouse studies suggest CFL1 inhibitors could help treat autism. CFL1 is involved in actin depolymerization and mutations in SHANK3 and other actin regulators are associated with risk of autism. In the mice,...
BC Innovations | Jun 4, 2015
Translation in Brief

Treating autism via actin

A study out of the University at Buffalo solidifies the actin dysregulation hypothesis of autism and identifies the actin regulator cofilin 1 (CFL1) as a therapeutic target in patients with mutations in the scaffold protein...
BC Innovations | Oct 2, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Infectious disease HIV Cofilin 1 (non-muscle) (CFL1) Studies in cell culture suggest that inhibiting CFL1 could be useful for preventing latent...
Items per page:
1 - 5 of 5